Session

Emerging aspects in pathogenesis and treatment of IBD (Posters)

APL DOWNREGULATION IN T CELLS IN THE SETTING OF CHRONIC COLITIS
APL DOWNREGULATION IN T CELLS IN THE SETTING OF CHRONIC COLITIS

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS
ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

GREY MATTER VOLUME CORRELATES OF EXTRAINTESTINAL SYMPTOMS IN ACTIVE AND QUIESCENT CROHN’S DISEASE
GREY MATTER VOLUME CORRELATES OF EXTRAINTESTINAL SYMPTOMS IN ACTIVE AND QUIESCENT CROHN’S DISEASE

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

MACROPHAGES ACTIVATION IN NEWLY DIAGNOSED ILEOCOLONIC CROHN’S DISEASE
MACROPHAGES ACTIVATION IN NEWLY DIAGNOSED ILEOCOLONIC CROHN’S DISEASE

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL
LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

VEGF-RELATED ANTIBODIOME CHARACTERIZES PATIENTS WITH CROHN’S DISEASE AND DIFFERENTIATES THE LOCATION OF INFLAMMATION
VEGF-RELATED ANTIBODIOME CHARACTERIZES PATIENTS WITH CROHN’S DISEASE AND DIFFERENTIATES THE LOCATION OF INFLAMMATION

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

HEMATOPOIETIC STEM CELL GENE THERAPY AS A NOVEL THERAPEUTIC APPROACH FOR SEVERE NOD2-DEFICIENT CROHN’S DISEASE
HEMATOPOIETIC STEM CELL GENE THERAPY AS A NOVEL THERAPEUTIC APPROACH FOR SEVERE NOD2-DEFICIENT CROHN’S DISEASE

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION
GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION

Emerging aspects in pathogenesis and treatment of IBD (Posters)  et al.

ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS
ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS

MACROPHAGES ACTIVATION IN NEWLY DIAGNOSED ILEOCOLONIC CROHN’S DISEASE
MACROPHAGES ACTIVATION IN NEWLY DIAGNOSED ILEOCOLONIC CROHN’S DISEASE

LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL
LDN-051 A NOVEL FECAL BIOMARKER FOR MONITORING DISEASE ACTIVITY AND THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASES – RESULTS OF A PHASE 2 CLINICAL TRIAL

VEGF-RELATED ANTIBODIOME CHARACTERIZES PATIENTS WITH CROHN’S DISEASE AND DIFFERENTIATES THE LOCATION OF INFLAMMATION
VEGF-RELATED ANTIBODIOME CHARACTERIZES PATIENTS WITH CROHN’S DISEASE AND DIFFERENTIATES THE LOCATION OF INFLAMMATION

HEMATOPOIETIC STEM CELL GENE THERAPY AS A NOVEL THERAPEUTIC APPROACH FOR SEVERE NOD2-DEFICIENT CROHN’S DISEASE
HEMATOPOIETIC STEM CELL GENE THERAPY AS A NOVEL THERAPEUTIC APPROACH FOR SEVERE NOD2-DEFICIENT CROHN’S DISEASE

GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION
GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION

APL DOWNREGULATION IN T CELLS IN THE SETTING OF CHRONIC COLITIS
APL DOWNREGULATION IN T CELLS IN THE SETTING OF CHRONIC COLITIS

GREY MATTER VOLUME CORRELATES OF EXTRAINTESTINAL SYMPTOMS IN ACTIVE AND QUIESCENT CROHN’S DISEASE
GREY MATTER VOLUME CORRELATES OF EXTRAINTESTINAL SYMPTOMS IN ACTIVE AND QUIESCENT CROHN’S DISEASE

Item 1 - 16 / 16
1